Clinical trials: Salmonella Infections
Typhoid
Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults
This study is to investigate the safety, tolerability and immunogenicity of the typhoid fever vaccine candidate M01ZH09 manufactured at commercial scale, at a new manufacturing facility.
- Trial name
- NCT00679172
- Testing
- Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (Cohort 2), Dose of 1.1 x 10^10 CFU (Cohort 3)
- Where
- 3 sites in United States
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Salmonella
Safety and Immunogenicity of CVD 1902 Oral Attenuated Vaccine to Prevent S. Paratyphi A Infection
The purpose of this study is to determine whether CVD 1902 (a live, attenuated, oral vaccine) is safe and effective in the prevention of Salmonella enterica serovar paratyphi A infection.
- Trial name
- NCT01129453
- Testing
- CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine
- Where
- 2 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Typhoid Fever
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants
This phase 2 trial is aimed to obtain information on the safety and immunogenicity of the Vi-CRM197 in subjects from various age groups in India and Pakistan where Typhoid Fever is highly endemic and an efficacious vaccine…
- Trial name
- NCT01229176
- Testing
- Vi-CRM197 vaccine, Vi Polysaccharide (PS) vaccine, Pneumococcal conjugate vaccine
- Where
- 2 sites in India, Pakistan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Novartis
Typhoid Fever
Vellore Typhoid Vaccine Impact Trial
This cluster randomised trial will examine the impact of introducing TyphiBEV, a typhoid conjugate vaccine licensed in India, on the incidence of typhoid fever in a high burden urban setting in South India.
- Trial name
- VEVACT (NCT05500482)
- Testing
- Typhoid conjugate Vaccine
- Where
- India
- Volunteers
- 72,400 people, healthy volunteers welcome
- Sponsor
- Christian Medical College, Vellore, India
Typhoid Fever
Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants
This is an observer-blinded, comparative, single dose, clinical phase II/III study to assess the immunogenicity and safety of EuTCV compared to Typhoid conjugate vaccine in healthy Filipino participants aged 6 months to 45 years.
- Trial name
- NCT04830371
- Testing
- EuTCV (Vi-CRM Typhoid conjugate vaccine), Typbar-TCV
- Where
- 2 sites in Philippines
- Volunteers
- 444 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Typhoid and Paratyphoid Fevers
TY800 Dose Escalation (Typhoid)
The purpose of this research study is to determine whether a new vaccine for typhoid fever is safe and effective. This study will also look at what effects (good and bad) this new vaccine, Ty800, has on the volunteers.
- Trial name
- NCT00269295
- Testing
- Ty800
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Salmonella Infections, Salmonella Typhimurium
Challenge Non-Typhoidal Salmonella (CHANTS) Study
This protocol describes the challenge non-typhoidal Salmonella (CHANTS) study. This is a first-in-human phase 1, double-blinded, randomised, dose-escalation human infection study, conducted in healthy volunteers aged 18 to 50…
- Conditions
- Salmonella Infections, Salmonella Typhimurium, Non-typhoidal Salmonella (NTS), Invasive Non-Typhoidal Salmonella Disease
- Trial name
- CHANTS (NCT05870150)
- Testing
- Salmonella Typhimurium
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Imperial College Healthcare NHS Trust
Typhoid
Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso
Typhoid fever is an illness that may cause mild effects in children, such as fever and feeling tired, or it may cause serious effects-- even death.
- Trial name
- NCT03614533
- Testing
- Vi-Typhoid Conjugate Vaccine (Vi-TCV), Inactivated Poliovirus Vaccine (IPV)
- Where
- Burkina Faso
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Enteric Fever, Typhoid Fever
Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India
The purpose of this study is to evaluate the impact of a government-led typhoid conjugate vaccine introduction program on typhoid disease burden in Navi Mumbai, India.
- Conditions
- Enteric Fever, Typhoid Fever, Salmonella Typhi Infection
- Trial name
- NCT03554213
- Testing
- Typhoid Conjugate Vaccine
- Where
- 6 sites in India
- Volunteers
- 17,292 people, healthy volunteers welcome
- Sponsor
- Stanford University
Typhoid
Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)
This is a multicenter, randomized, observer-blinded, controlled, immune equivalence study of a multi-dose (MD) formulation with 2PE preservative of SK bioscience Vi-DT compared to single dose (SD) formulation without preservative…
- Trial name
- NCT04204096
- Testing
- Vi-DT (Multi-dose formulation), Vi-DT (Single dose formulation), Control Vaccine
- Where
- 4 sites in Philippines
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid Fever, Enteric Fever
Understanding Typhoid Disease After Vaccination
Using an established model of human typhoid infection, whereby healthy adults are deliberately infected with typhoid-causing bacteria, the investigators will determine how effective a new oral typhoid vaccine (M01ZH09) is in…
- Conditions
- Typhoid Fever, Enteric Fever, Typhoid
- Trial name
- NCT01405521
- Testing
- Ty21a, M10ZH09 vaccine
- Where
- United Kingdom
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Typhoid
Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine
This is a Phase I, Randomized, observer-blinded, age de-escalating study. The study objectives are: 1. To evaluate the safety of 25 μg of Vi-DT typhoid conjugate vaccine administered at 0 and 4 weeks. 2.
- Trial name
- NCT02645032
- Testing
- Vi-DT, Typhim Vi®, VAXIGRIP®
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Cholera, Typhoid
Studies of Immune Responses to Orally Administered Vaccines in Developing Country
The efficacy and immunogenicity of enteric vaccines have generally been found to be lower in children in the developed than in the developing countries.
- Trial name
- NCT01019083
- Testing
- Control, Zinc Sulphate, Albendazole and Secnidazole
- Where
- Bangladesh
- Volunteers
- 1,016 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Typhoid Fever, Enteric Fever
Vaccines Against Salmonella Typhi
Using an established model of human typhoid infection, whereby healthy adults are deliberately exposed to typhoid-causing bacteria, the investigators will determine how effective a new typhoid conjugate vaccine (Vi-TCV) is in…
- Trial name
- VAST (NCT02324751)
- Testing
- Vi-TCV, Vi-PS Vaccine, Control (Men ACWY)
- Where
- United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Typhoid Fever
Diagnosis and Staging of Typhoid Fever Using Surface-enhanced Raman Spectroscopy Liquid Biopsy
The goal of this project is to adapt the gold nanoparticle-based surface-enhanced Raman spectroscopy (SERS) technology to clinical application.
- Trial name
- NCT06546982
- Testing
- Surface-enhanced Raman Spectroscopy
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Aachen
Enteric Fever Caused by Salmonella Enterica Serovar Paratyphi A
Understanding Paratyphoid Infection
Enteric fever is responsible for over 20 million illnesses and 200,000 deaths each year. S. Paratyphi A accounts for a substantial and increasing proportion of these cases, as high as 90% in some regions of Asia.
- Trial name
- NCT02100397
- Testing
- Salmonella enterica serovar Paratyphi A (strain NVGH308)
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Typhoid
Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi
This study will evaluate the efficacy of a Typhoid conjugate vaccine (Vi-TCV) in Malawi, Africa among children age 9 months through 12 years.
- Trial name
- NCT03299426
- Testing
- Vi-Typhoid Conjugate Vaccine (Vi-TCV), Meningococcal A Conjugate Vaccine (MCV-A)
- Where
- Malawi
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Risk Reduction
Blood Donor CVD 5000
This is an open-label, non-randomized study. Volunteers will be vaccinated with the typhoid oral vaccine, Vivotif. Vivotif has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries.
- Trial name
- NCT03971669
- Testing
- Vivotif Typhoid Oral Vaccine
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Typhoid Fever
CVD 909 Vi Prime Boost Study
The purpose of this research study is to see if giving a typhoid vaccine by mouth (an experimental vaccine, CVD 909) before giving a vaccine shot (Typhim Vi) will result in a better immune response than giving Typhim Vi vaccine…
- Trial name
- NCT00326443
- Testing
- CVD 909, Vi Polysaccharide
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)